Contribute Try STAT+ Today

On the eve of a widely anticipated trial, Johnson & Johnson (JNJ) agreed on Saturday to pay $230 million to the state of New York to settle a lawsuit alleging that the company helped fuel the devastating opioid crisis.

The deal comes as negotiations intensify with the health care giant and three of the nation’s largest pharmaceutical wholesalers to complete a sweeping $26 billion settlement of thousands of other lawsuits. The settlement includes an additional $33 million in attorney fees and costs, as well as a commitment from J&J to halt opioid sales, a step the company said it has already taken (you can read the settlement here).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment